Lawrence E. Leibowitz - 25 Oct 2022 Form 4 Insider Report for Enfusion, Inc.

Reporting relationship: Director
Issuer ticker: N/A
Reported as of: 25 Oct 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Oct 2022, 21:20:40 UTC
Prior SEC filing: 01 Sep 2022
Next SEC filing: 27 Jan 2023
Source filing: View source filing
Reporting owner signature: /s/ Blake Nielsen, as Attorney-in-Fact

Key filing fact

Lawrence E. Leibowitz filed Form 4 for Enfusion, Inc. on 27 Oct 2022.

Key facts

This page summarizes Lawrence E. Leibowitz's Form 4 filing for Enfusion, Inc..
1 reported transaction and 0 derivative rows are listed below.
Accepted by SEC: 27 Oct 2022, 21:20.

Change

Previous filing in this sequence was filed on 01 Sep 2022.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ENFN transaction

Class A Common Stock

Award

Transaction value: $0
Shares: +7,239
Change %: +14%
Price: $0.000000
Shares after: 57,601
Date: 25 Oct 2022
Ownership: Direct
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

Consists of fully vested shares issued under the Enfusion, Inc. 2021 Stock Option and Incentive Plan in connection with the previously disclosed pre-IPO termination of the Enfusion Ltd. LLC Change in Control Bonus Plan (the "Shares").